Helicobacter pylori strain diversity was investigated in infected persons by collection of multiple biopsies before and after therapy failure. It was demonstrated by random amplification of polymorphic DNA polymerase chain reaction that patients may be infected with a mixed population of H. pylori strains. Most patients were colonized with a predominant strain accompanied by up to 5 variant strains. The use of antimicrobials resulted in an altered distribution of the strains present, but the predominant strain usually remained. Patients may be infected with a mixed population of metronidazole-sensitive and -resistant strains at one time, with metronidazole-based therapy selectively enriching for a resistant population.
Helicobacter pylori is a spiral, gram-negative, microaerophilic bacterium responsible for chronic, acute, and atrophic gastritis and gastric and duodenal ulcer diseases [I] . Additionally, H. pylori infection is a necessary but not sufficient factor in initiating gastric adenocarcinoma and lymphoma [2] .
Effective treatment of H pylori infection has proved difficult, with poor efficacy and the development of resistance to some antimicrobials, necessitating the use of combination therapies [3 -6] . The now classic triple therapy (a nitroimidazole, bismuth, and either amoxicillin or tetracycline) is reported efficacious in >90% of patients, but significant treatment failures have been reported [4, 6] . A major contributing factor to the failure of such therapy is the organism's ability to develop resistance to the nitroimidazoles (e.g., metronidazole). The ecologic niche occupied by H. pylori may prevent sufficient concentrations of the drug reaching the organism; hence, sublethal concentrations may select for resistant strains or augment the development of resistance in previously sensitive strains.
A variety of DNA-based methods have been used to identify and type H, pylori, and it is recognized that great genetic diversity exists between isolates from different persons [7R 11]. Minor differences in DNA patterns of isolates from a single patient have been reported, suggesting that > 1 strain may coexist within the human stomach [7 -9] .
The aims of this study were to investigate H. pylori strain diversity in infected persons by sampling multiple sites within the stomach and to determine the effect of antibiotic treatment on such strains with respect to metronidazole resistance in order to improve our understanding of therapy failure.
Materials and Methods
Patients. Patients presenting for routine endoscopic examination, infected with H. pylori and having had no previous treatment for this infection, were invited to participate in the study. For culture, 10 gastric biopsies were taken, 5 each from the antrum and body of the stomach. Patients were treated with colloidal bismuth subcitrate (110 mg) and tetracycline (250 mg), four times daily, and metronidazole (200 mg), three times daily, for 2 weeks. If therapy failure was evident, repeat biopsies were collected 6 weeks after cessation of treatment.
Bacterial isolates. Biopsies were inoculated onto blood agar base no. 2 (Oxoid, Basingstoke, UK) containing 5% horse blood (Oxoid), 5 .0 mg/mL vancomycin (Eli Lilly, Indianapolis), 2.5 j..Lg/ mL polymyxin B (Sigma, St. Louis), 2.5 mg/mL trimethoprim (Sigma), and 2.0 j..Lg/mL fungizone (E.R. Squibb, Princeton, NJ), then incubated at 37°C with 10% CO 2 in air and 95% relative humidity. From each biopsy, 2 isolated colonies were selected at random and replated. Isolates were identified as H. pylori by routine criteria, then stored in brain-heart infusion (BHI)broth (Oxoid) with 20% glycerol (Ajax Chemicals, Auburn, Australia) inliquid nitrogen.
Metronidazole susceptibility. Isolates of H. pylori were suspended in BHI broth containing 20% glycerol and adjusted to a McFarland turbidity of 1.0 (~10 8 cfu/mL). Using a sterile swab, the suspensions were plated onto antibiotic-free Isosensitest agar (Oxoid) enriched with 5% horse blood. Metronidazole disks (5 ug; Oxoid) were applied to the plates, which were incubated microaerophilically at 37°C for 72 h. Isolates were considered sensitive if a clear zone was visible around the disk (annular radius >2 nun). If no clear zone was observed, the susceptibility test was repeated using metronidazole E-test strips (AB Biodiscs, Solna, Sweden). Isolates were considered resistant if they gave a MIC reading of >8 p,g/mL.
Preparation oftemplate DNA. A loopful of H. pylori cells (72 h) was inoculated into 500 p,L of 50% ethanol and then vortexed. Next, 500 p,L of phenol-chloroform-isoamyl alcohol (25:24: 1; Sigma) was added and mixed, and the suspension was centrifuged at 16,100 g for 3 min. The upper phase was used immediately or stored at -20°C until required. The A 260 and AnD of the DNA preparations were measured in a spectrophotometer (Beckman DU-600; Beckman Instruments, Brea, CA) and an A26o-to-Ano ratio of? I was accepted as suitable for use in the random amplification of polymorphic DNA (RAPD) polymerase chain reaction (PCR). Preparations were diluted to give a concentration of 15-20 p,g/ mL DNA based on the A 260 reading.
RAPD PCR. A modified method of RAPD PCR [10] [10] (sequence AACGC-GCAAC) was used. The PCR product was analyzed using standard agarose gel electrophoresis.
Reproducibility ofRAPD PCR. Because of the low stringency of the RAPD PCR technique, very strict control procedures were used to ensure consistent and reproducible results. A positive (known sample of H. pylori DNA) and a negative control were included in each set of PCR reactions. Most isolates were tested by 2 persons on separate occasions, using fresh DNA preparations, with the same RAPD profiles achieved. A second arbitrary primer (primer 1290 [10] ) was also used to type selected isolates to confirm the results obtained with primer 1281.
Results
Of 108 patients who had H. pylori cultured from their initial biopsies, 42 returned for the follow-up endoscopic examination. Patients were predominantly Greek in origin (57%), with other European (21 %), Australian (17%), and Vietnamese (5%) nationalities also represented. There were 20 men and 22 women, with ages ranging between 20 and 78 years (mean age, 45.5). Therapy failed in 17 patients (40.5%), 12 men and 5 women. These patients were given a second treatment regimen consisting of colloidal bismuth subcitrate, tetracycline, and omeprazole (110, 250, and 20 mg, respectively, four times daily for 2 weeks); 5 remained H. pylori culture-positive on their third visit. Comparisons of age and place of origin indicate that these factors had little effect on treatment outcome.
A mixed group of metronidazole-sensitive and -resistant isolates was obtained from patients before therapy (table 1) . Almost all isolates obtained after therapy failure were resistant (table 2). In patients infected with sensitive strains before therapy, therapy failed only once (4.5%). In contrast, in patients infected with either resistant strains or a mixed population of sensitive and resistant strains, therapy failed in 16 (80%).
When therapy failure was evident, isolates were analyzed by RAPD PCR. The RAPD profiles of isolates from a particular patient were distinct from the RAPD profiles of isolates from other patients (figure lA). Minor differences in RAPD patterns of some isolates from the same patient were noted by the presence or absence of particular bands. If these profiles differed by more than one band, the isolates were considered to represent different strains (figure IB). Results from RAPD PCR using the second primer confirmed the strain differentiation obtained using the original primer.
The number of strains identified in a single patient varied from 1 to 6 (table 2). The majority of patients had a single predominant strain before and after therapy failure. Some patients had a new strain predominating (e.g., patients 9406, 9410, 9411) or had an altered distribution of strains (e.g., patient 9414) after therapy. There was no apparent difference in the distribution of strains between the antrum and body of the stomach, with most strains isolated from both areas on at least one occasion. H pylori was not always isolated from all biopsy sites, and in some cases both isolates from each biopsy did not survive storage. In a few cases, isolates from the same biopsy site differed in their RAPD profile.
After antibiotic treatment, some patients remained colonized with the same strains as detected before treatment (table 2; patients 9401-9405). New strains appeared in some patients' follow-up biopsies (patients 9406-9411), and other strains were not detected after therapy (patients 9412-9416). Furthermore, patient 9417, who appeared cured of infection on the first follow-up visit, was later found to be infected with the initial strain and with an additional strain not previously detected. : Colloidal bismuth subcitrate, tetracycline, and omeprazolc (110, 250, and 20 mg, 4 times daily) for 2 weeks. 'Isolates not producing RAPD (random amplification of polymorphic DNA) profile using primer selected were not ineluded in total count of infecting strains and are listed as strains X 1-X9. Lack of RAPD profile docs not indicate that isolates are identical: however, they are likely to be different from other isolates that did give a profile with selected primer. These isolates were typed using other arbitrary primers, with resultant RAPD profiles (data not shown).
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Gastric acidity and the environment in which H. pylori resides, beneath the mucous layer and within the gastric pits, results in many antibiotics being ineffective in therapy. Furthermore, the rapid development of resistance to many classes of antimicrobials reduces the number of effective agents that can be used. As a result, combination therapies are required to effect successful treatment.
The success of therapy in this study was lower than reported by other investigators [3 -6] . We attribute this to the high prevalence of metronidazole resistance in the patient sample. The aim of this study, however, was not to evaluate the efficacy of this therapy regimen; hence, only patients who returned for follow-up endoscopic examination with H. pylori cultured from their initial and follow-up biopsies were evaluated.
Techniques such as ribotyping [8] , RAPD PCR [10] , restriction enzyme analysis [11] , and pulsed-field gel electrophoresis [12] demonstrate that there is considerable genomic variability between isolates of H. pylori from different patients. The diversity of H. pylori strains within a single patient has not been extensively examined; most investigations consider a single biopsy specimen as representative of the entire bacterial population in the stomach. Some studies examining isolates from consecutive biopsies of single patients and multiple isolates from single biopsies have shown these to be indistinguishable [9, 10, 13, 14] .
Majewski and Goodwin [11] showed profile changes with restriction enzyme analysis when subsequent biopsies were analyzed, and Owen et al. [8] found by ribotyping a high degree of heterogeneity in isolates from 3 biopsies of a single patient, suggesting that different areas of the stomach may harbor variant subpopulations. Others have identified> 1 strain on a single occasion [7, 12] , suggesting that patients may be infected with > 1 strain of H. pylori.
This study is unique in that we analyzed isolates from up to 10 biopsies from patients before and after therapy. We confirmed that pronounced DNA diversity exists between H. pylori strains from different patients. Importantly, we have established that patients may be colonized with a mixed population of H. pylori at one time, with up to 6 strains present in 1 patient. The majority of patients had a predominant infecting strain, distributed between the antrum and body of the stomach. The other strains identified were represented by a few isolates and could be found in either the antrum or the body or in both sites in the stomach. In a few cases, 2 strains were found to coexist at a single biopsy site. Marshall et al. [14] reported that a homogenous population of H. pylori exists within a single biopsy sample; however, occasionally some bands were lacking from the RAPD profile.
RAPD PCR uses a single, randomly selected primer for DNA synthesis in a low-stringency PCR amplification cycle. This primer may match or almost match genomic DNA to result in a distinctive, strain-specific pattern. A difference of more than one band in an RAPD pattern suggests that there is sufficient polymorphic DNA diversity in an isolate to indicate that a new genomic variety is infecting a patient [15] . It remains to be seen whether these are all new strains of H. pylori or whether 5 6 7 8 9 10 11 12 13 14 1 2 3 4
Before therapy, some strains were observed to display both metronidazole-resistant and -sensitive phenotypes, such as strains Dl, FI, and M2 (table 2) . After treatment failure, some sensitive strains were absent (e.g., strains 11, N3, and N4), whereas other sensitive strains had developed resistance (e.g., strains AI, F2, and N2). Conversely, strains L3, M2, P2, and P4, which contained resistant isolates, were identified before but not after therapy. they are simply subtypes of a predominant strain. It is possible that changes or mutations, such as genomic rearrangement and natural transformation, may lead to strain development during the lifelong infection of a patient [9] . However, it may suggest infection with multiple strains of H. pylori during childhood or later in life. This may have implications in regard to understanding the natural history of H. pylori infection.
Metronidazole resistance was observed in some strains isolated before therapy, yet after therapy, almost all were resistant. Additionally, some isolates with indistinguishable RAPD patterns were mixed with respect to susceptibility and resistance to metronidazole. Therapy failure did not usually result in a change in the predominant strain within a patient, yet in some cases this did occur. Some strains persisted in a patient regardless of their susceptibility to metronidazole before treatment, while others were detected only after treatment, possibly as a result of decreased competition. Thus, metronidazole resistance may be induced on exposure to this antimicrobial in previously sensitive isolates, and therapy essentially selectively enriches the stomach with these resistant strains.
Our results demonstrate that persons may be colonized with one or more distinct strains of H. pylori, often with one strain predominating. Metronidazole-based treatment results in the development and selection for metronidazole-resistant strains and may also contribute to an altered distribution of strains present.
